Please use this identifier to cite or link to this item: http://hdl.handle.net/10553/47482
Title: Classifying new anti-tuberculosis drugs: rationale and future perspectives
Authors: Tiberi, Simon
Scardigli, Anna
Centis, Rosella
D'Ambrosio, Lia
Muñoz-Torrico, Marcela
Salazar-Lezama, Miguel Ángel
Spanevello, Antonio
Visca, Dina
Zumla, Alimuddin
Migliori, Giovanni Battista
Caminero Luna, Jose A. 
UNESCO Clasification: 32 Ciencias médicas
320508 Enfermedades pulmonares
Keywords: Anti-TB drugs
Bedaquiline
Delamanid
Fluoroquinolones
Linezolid, et al
Issue Date: 2017
Journal: International Journal of Infectious Diseases 
Abstract: The classification of anti-tuberculosis (TB) drugs is important as it helps the clinician to build an appropriate anti-TB regimen for multidrug-resistant (MDR) and extensively drug-resistant (XDR) TB cases that do not fulfil the criteria for the shorter MDR-TB regimen. The World Health Organization (WHO) has recently approved a revision of the classification of new anti-TB drugs based on current evidence on each drug. In the previous WHO guidelines, the choice of drugs was based on efficacy and toxicity in a step-down manner, from group 1 first-line drugs and groups 2-5 second-line drugs, to group 5 drugs with potentially limited efficacy or limited clinical evidence. In the revised WHO classification, exclusively aimed at managing drug-resistant cases, medicines are again listed in hierarchical order from group A to group D. In parallel, a possible future classification is independently proposed. The aim of this viewpoint article is to describe the evolution in WHO TB classification (taking into account an independently proposed new classification) and recent changes in WHO guidance, while commenting on the differences between them. The latest evidence on the ex-group 5 drugs is also discussed.
URI: http://hdl.handle.net/10553/47482
ISSN: 1201-9712
DOI: 10.1016/j.ijid.2016.10.026
Source: International Journal of Infectious Diseases[ISSN 1201-9712],v. 56, p. 181-184
Appears in Collections:Artículos
Show full item record

SCOPUSTM   
Citations

60
checked on Aug 14, 2022

Page view(s)

14
checked on May 21, 2022

Google ScholarTM

Check

Altmetric


Share



Export metadata



Items in accedaCRIS are protected by copyright, with all rights reserved, unless otherwise indicated.